SCHEMBL8959604

SCHEMBL8959604

CC(C)c1cc2[nH]ccc2cc1F

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.62
EIF4A3 P38919 1/20 0.47
AHR P35869 6/20 0.46
CSNK2A1 P68400 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP2A6 P11509 3/20 0.37
NR4A2 P43354 2/20 0.37
CMA1 P23946 1/20 0.37
F7 P08709 1/20 0.37
LTA4H P09960 1/20 0.37
F3 P13726 1/20 0.37
TYR P14679 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
ALOX15 P16050 1/20 0.37
RAD51 Q06609 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12110240 0.93 GPR84 (0.62) GPR84EIF4A3AHRCSNK2A1MEN1
SCHEMBL16744197 0.84 GPR84 (0.48) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL15763108 0.78 CSNK2A1 (0.50) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL188052 0.78 GPR84 (1.00) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL19668855 0.76 GPR84 (0.44) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL19085872 0.75 GPR84 (0.40) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL14602896 0.75 GPR84 (0.40) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL579164 0.75 GPR84 (0.69) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL26801536 0.74 GPR84 (0.42) GPR84AHRCSNK2A1MEN1POLB
SCHEMBL8526222 0.74 CSNK2A1 (0.55) GPR84AHRCSNK2A1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112830-A1 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-05-30 WO disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-5494928-A FOR CENTRAL NERVOUS SYSTEM DISORDERS, BLOCKING SEROTONIN RECEPTORS, ANTIDEPRESSANTS HOFFMANN-LA ROCHE INC. (US) 1996-02-27 US disclosed
CN-1105988-A 1-amino-ethylindole-derivatives HOFFMANN LA ROCHE (CH) 1995-08-02 CN disclosed
EP-0655440-A2 1-Aminoethylindoles F. HOFFMANN-LA ROCHE AG (CH) 1995-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP GPR84 162/4885EIF4A3 2019/4885AHR 3562/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP GPR84 162/4885EIF4A3 2019/4885AHR 3562/4885
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS GPR84 3460/4885EIF4A3 2047/4885AHR 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.